Cannabis and Bipolar Disorder
Why cannabis use worsens bipolar outcomes despite subjective relief, and what the research shows.
This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.
People with bipolar disorder use cannabis far more than the general population, often because it feels good short-term—better sleep, quieter mind. But the evidence is stark: cannabis users with bipolar disorder cycle faster, land in hospital more often, and do worse on their mood stabilizers. There is no RCT evidence that cannabis or CBD treats any part of bipolar disorder. If this is you, the move is to tell your doctor, not to find the 'right strain.'
Not Medical Advice
This article is not medical advice. Bipolar disorder is a serious psychiatric condition that can be life-threatening if untreated. Do not start, stop, or change any medication based on what you read here. If you have bipolar disorder, decisions about cannabis use should involve your prescribing clinician. If you are in crisis, contact emergency services or a crisis line (in the US, call or text 988).
Plain-Language Summary
Bipolar disorder is a mood disorder characterized by episodes of mania (or hypomania) alternating with, in most patients, episodes of depression. Standard medical treatment includes mood stabilizers—lithium, valproate, lamotrigine, atypical antipsychotics—typically combined with psychotherapy and sleep regulation Strong evidence[1].
People with bipolar disorder use cannabis at substantially higher rates than the general population. Meta-analyses estimate lifetime cannabis use disorder in bipolar I patients at 20–30%, compared to roughly 6–8% in the general adult population Strong evidence[2][3]. Users commonly report that cannabis helps them sleep, quiets racing thoughts, or lifts mood.
The research picture diverges sharply from these subjective reports. Multiple prospective cohort studies associate cannabis use with earlier illness onset, more frequent manic episodes, faster mood cycling, more psychiatric hospitalizations, and poorer adherence to mood stabilizers Strong evidence[4][5]. No randomized controlled trials show that whole-plant cannabis, THC, or CBD improves any phase of bipolar disorder—mania, depression, or relapse prevention No data.
What Probably Works
Nothing, on current evidence. There is no cannabis preparation—whole flower, THC isolate, CBD, or combined—backed by adequately powered randomized controlled trials for bipolar mania, bipolar depression, or recurrence prevention No data.
This absence reflects real scientific uncertainty, not lack of research interest. The studies conducted to date are small, short-duration, and mostly negative or inconclusive. Until larger and longer RCTs are completed with explicit bipolar populations, no cannabis-based intervention can be said to 'probably work' for this condition.
What Might Work (Weak or Preliminary Evidence)
CBD as an adjunct to mood stabilizers. CBD has demonstrated antipsychotic and anxiolytic effects in small randomized trials in schizophrenia and social anxiety disorder Weak / limited[6][7]. By biological extension, some clinicians have hypothesized that CBD might benefit bipolar patients with concurrent anxiety or psychotic features.
One 2020 open-label pilot study enrolled 35 patients with acute bipolar depression who received CBD 150–300 mg/day added to their existing mood stabilizer Weak / limited[8]. Participants tolerated the treatment without serious adverse events, but CBD did not separate from baseline on depression severity measures. This is hypothesis-generating, not evidence of clinical benefit.
Short-term insomnia and anxiety relief. Many bipolar patients report subjective improvement in sleep onset and anxiety in the short term after cannabis use Anecdote. Self-report surveys confirm that sleep and anxiety relief are among the most common stated reasons for use [9]. However, subjective relief does not predict long-term illness course improvement; longitudinal studies show that people reporting these benefits often have worse overall outcomes.
What Doesn't Work or Has Weak Evidence Against
THC-dominant cannabis for mania. Multiple prospective cohort studies, including one population-based study of over 2000 individuals, show that cannabis use precedes and predicts manic episodes—including in patients previously stable on mood stabilizers Strong evidence[4][5]. The biological mechanism is consistent: THC increases dopamine release in the mesolimbic system and has documented pro-psychotic effects, both of which could precipitate mania.
Cannabis as a 'natural mood stabilizer.' This claim circulates in online patient forums and wellness sites but has no controlled trial support. Longitudinal evidence points in the opposite direction Strong evidence[4][5].
Strain selection by indica/sativa label. The traditional indica/sativa distinction—based on plant morphology, not chemistry—does not reliably predict psychoactive effects Strong evidence[10]. Cannabinoid and terpene composition varies widely within each category. Choosing a product by marketing label ('indica for sleep,' 'sativa for mood') is not a defensible treatment strategy.
What We Don't Know
- Whether pure CBD at clinical doses has an adjunctive role. The one bipolar depression pilot was inconclusive [8]. It remains unknown whether CBD at 300–800 mg/day (doses used in epilepsy and psychosis trials) would show benefit in larger samples, longer follow-up, or as an add-on to specific mood stabilizers.
- The true causal pathway. Prospective cohort studies show association between cannabis use and worse bipolar outcomes, but causation, reverse causation (sicker patients self-medicate more), and unmeasured confounding (shared genetic vulnerability) cannot be fully disentangled Disputed[4][5].
- A safe dose threshold. It is unknown whether a threshold exists below which cannabis is neutral rather than harmful for people with bipolar disorder.
- Real-world drug interaction magnitude. CBD inhibits CYP2C19, CYP3A4, and CYP2C9 [11]. These enzymes metabolize valproate (hepatotoxicity documented in epilepsy trials) and potentially lamotrigine, lithium (primarily renal clearance), and quetiapine. Whether these interactions reach clinical significance at common consumer CBD doses is unresolved.
Comparison with Standard Treatments
Standard pharmacological treatments for bipolar disorder have decades of randomized controlled evidence:
- Lithium remains the most robustly evidenced mood stabilizer, reduces suicide risk, and is first-line for bipolar I disorder Strong evidence[1][12].
- Valproate is effective for acute mania Strong evidence[1].
- Lamotrigine is effective for prevention of bipolar depression Strong evidence[1].
- Atypical antipsychotics (quetiapine, olanzapine, lurasidone, cariprazine) have RCT support for various acute and maintenance phases Strong evidence[1].
- Psychotherapies (CBT, family-focused therapy, interpersonal and social rhythm therapy) reduce relapse risk Strong evidence[1].
Cannabis has no comparable evidence base for any phase of bipolar disorder. Using it instead of these treatments is not supported by evidence.
Risks
Mania and psychosis. THC can trigger manic and psychotic episodes, especially with high-potency products and in younger users Strong evidence[4][13]. In people with bipolar disorder, this risk is amplified because the disorder confers baseline vulnerability to these states.
Faster mood cycling and more hospitalizations. Prospective cohorts consistently show that cannabis-using bipolar patients have more frequent and more severe mood episodes than non-using bipolar patients matched on other variables Strong evidence[3][5]. Psychiatric hospitalizations are more common.
Poor medication adherence. Cannabis use disorder is associated with lower adherence to mood stabilizers [3], which is itself the strongest predictor of relapse and hospitalization in bipolar disorder.
Drug interactions. CBD inhibits several CYP450 enzymes (CYP2C19, CYP3A4, CYP2C9) and can raise serum levels of valproate (with documented hepatotoxicity in epilepsy trials), clobazam, and potentially lamotrigine and quetiapine Strong evidence[11]. Cannabis and Polypharmacy Risks provides details.
Cannabis use disorder. People with bipolar disorder are at substantially elevated risk of developing cannabis use disorder compared to the general population Strong evidence[2]. CUD itself predicts worse bipolar outcomes.
Suicide risk. Cannabis use in bipolar disorder is associated with increased suicidal ideation and behavior in multiple cohort studies Strong evidence[14]. The mechanism is unclear but may involve medication non-adherence, mood destabilization, or shared underlying risk.
Bottom Line
Cannabis is not a treatment for bipolar disorder. People with bipolar disorder who use cannabis tend to have more severe illness and worse long-term outcomes, even if they report short-term symptom relief. CBD-only products carry lower risk of acute mood destabilization than THC-dominant cannabis, but they are not proven helpful for bipolar disorder and have documented interactions with several mood stabilizers.
If you have bipolar disorder and use or are considering using cannabis, the most practical advice this article offers is: speak with your psychiatrist or mood disorder specialist openly about it. Do not stop your mood stabilizer. Ask about your specific medications and any CBD interactions. If you are struggling with depression or insomnia despite your current treatment, that is a signal to adjust your mood stabilizer regimen in consultation with your clinician—not to self-medicate with cannabis.
Sources
- Peer-reviewed Yatham LN, Kennedy SH, Parikh SV, et al. (2018). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders, 20(2), 97–170.
- Peer-reviewed Hunt GE, Malhi GS, Cleary M, Lai HM, Sitharthan T. (2016). Comorbidity of bipolar and substance use disorders in national surveys of general populations, 1990–2015: systematic review and meta-analysis. Journal of Affective Disorders, 206, 321–330.
- Peer-reviewed Lev-Ran S, Le Foll B, McKenzie K, George TP, Rehm J. (2013). Bipolar disorder and co-occurring cannabis use disorders: characteristics, co-morbidities and clinical correlates. Psychiatry Research, 209(3), 459–465.
- Peer-reviewed Henquet C, Krabbendam L, de Graaf R, ten Have M, van Os J. (2006). Cannabis use and expression of mania in the general population. Journal of Affective Disorders, 95(1–3), 103–110.
- Peer-reviewed Gibbs M, Winsper C, Marwaha S, Gilbert E, Broome M, Singh SP. (2015). Cannabis use and mania symptoms: a systematic review and meta-analysis. Journal of Affective Disorders, 171, 39–47.
- Peer-reviewed McGuire P, Robson P, Cubala WJ, et al. (2018). Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. American Journal of Psychiatry, 175(3), 225–231.
- Peer-reviewed Bergamaschi MM, Queiroz RH, Chagas MH, et al. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology, 36(6), 1219–1226.
- Peer-reviewed Pinto JV, Crippa JAS, Ceresér KM, et al. (2020). Cannabidiol as an adjunctive treatment for acute bipolar depression: a pilot study. Canadian Journal of Psychiatry, 65(7), 505–507.
- Peer-reviewed Ashton CH, Moore PB, Gallagher P, Young AH. (2005). Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. Journal of Psychopharmacology, 19(3), 293–300.
- Peer-reviewed Smith CJ, Vergara D, Keegan B, Jikomes N. (2022). The phytochemical diversity of commercial Cannabis in the United States. PLoS ONE, 17(5), e0267498.
- Peer-reviewed Brown JD, Winterstein AG. (2019). Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. Journal of Clinical Medicine, 8(7), 989.
- Peer-reviewed Cipriani A, Hawton K, Stockton S, Geddes JR. (2013). Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ, 346, f3646.
- Peer-reviewed Di Forti M, Quattrone D, Freeman TP, et al. (2019). The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry, 6(5), 427–436.
- Peer-reviewed Østergaard MLD, Nordentoft M, Hjorthøj C. (2017). Associations between substance use disorders and suicide or suicide attempts in people with mental illness: a Danish nation-wide, prospective, register-based study. Addiction, 112(7), 1250–1259.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Cannabis and Generalized Anxiety Disorder — Weak evidence for acute CBD effects; no proof of long-term benefit; high THC worsens anxie...
- Cannabis and Panic Disorder — Cannabis can trigger panic attacks; evidence for treatment is absent. Standard therapies w...
- Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.
- Cannabis Use Disorder — A clinical diagnosis defined by impaired control, withdrawal, and harm—treatable with beha...
- CBD and Anxiety — Strong evidence for one-time high-dose CBD before acute stressors; weak evidence for daily...